Raloxifene
- Generic Name
- Raloxifene
- Brand Names
- Evista, Optruma, Raloxifene Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27NO4S
- CAS Number
- 84449-90-1
- Unique Ingredient Identifier
- YX9162EO3I
- Background
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...
- Indication
Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
- Associated Conditions
- Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment
- Associated Therapies
- -
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00046137
- Locations
- 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician"., Dallas, Texas, United States
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035256
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sainte -Foy, Quebec, Canada
Raloxifene and Rimostil for Perimenopause-Related Depression
- Conditions
- Interventions
- First Posted Date
- 2002-02-07
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 65
- Registration Number
- NCT00030147
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2016-09-22
- Target Recruit Count
- 612
- Registration Number
- NCT00001848
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.